Middle East & Africa Clinical Trials Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Middle East & Africa clinical trials market size is expected to reach US$ 1,803.78 million by 2031 from US$ 1,234.57 million in 2023. The market is estimated to record a CAGR of 4.9% from 2023 to 2031.

Executive Summary and Middle East & Africa Clinical Trials Market Analysis:

The clinical trials market in the Middle East & Africa is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. The regional growth is attributed to rising rate of cancer and investments in developing healthcare infrastructure. Factors such as growing awareness of the advantages of clinical trials, government showing a propensity to spend on healthcare infrastructure and research are likely to further propel the clinical trials market growth during the forecast period.

Middle East & Africa Clinical Trials Market Strategic Insights

Get more information on this report Request Free Sample PDF

Middle East & Africa Clinical Trials Market Segmentation Analysis

Key segments that contributed to the derivation of the Middle East & Africa clinical trials market analysis are study design, indications, and phase type.

• Based on study design, the Middle East & Africa clinical trials market is bifurcated into interventional trials and expanded access trials. The interventional trials held a larger share of the market in 2023.
• Based on indications, the Middle East & Africa clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular, and others. The oncology held the largest share of the market in 2023.
• Based on phase type, the Middle East & Africa clinical trials market is segmented into phase I, phase II, and phase III. The phase I held the largest share of the market in 2023.

Middle East & Africa Clinical Trials Market Outlook

Clinical trials are conducted to determine if a new form of medical product, i.e., a drug, diet, or medical device, is safe and effective. The trials are mainly a part of the overall drug development process. According to the National Library of Medicine (NLM), ~52,000 new studies were registered with NLM (ClinicalTrials.gov) in 2020, and the number increased to ~58,000 in 2023. An upsurge in the number of clinical trials can be attributed to the rising prevalence of chronic diseases worldwide, which creates an immense demand for more effective treatments. The increasing complexity of clinical trials adds to the cruciality of the proper execution and overseeing of operations carried out in research-based organizations. To avoid errors due to improper execution, many research-based organizations outsource clinical trials to clinical research organizations (CROs). CROs assist in successfully implementing clinical trials through the services they offer through their high-quality facilities and deep subject matter expertise. They have gradually become a backbone of the clinical trial industry through their efficient and cost-effective operations that benefit trial sponsors. According to a blog published by Thermo Fisher Scientific, in 2022, CROs executed ~3 out of 4 clinical trials to reassure the clinical programs of drug developers, provide a wealth of expertise, drive time and cost efficiencies, and deliver customized, high-quality data. Thus, the increasing number of clinical trials, and the practice of outsourcing trials to CROs to boost cost-effectiveness and reduce errors are the major factors driving the clinical trials market growth.

Middle East & Africa Clinical Trials Market Country Insights

Based on country, the Middle East & Africa clinical trials market comprises Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held the largest share in 2023.

Despite being one of the most economically advanced African nations, South Africa faces many public health challenges. TB is one of the leading causes of death in South Africa. According to the 2021 World Health Organization (WHO) data, South Africa ranked eighth among the 30 high-burden countries, contributing to 86% of the reported incident TB cases globally. UNAIDS estimates that ~7.8 million people in the country are currently suffering from HIV. To treat the increasing cases of HIV, various clinical trials are being conducted in the country.

According to an article titled "TB trials transform treatment," published in June 2022, research was conducted in South Africa to find shorter and more effective treatments for drug-resistant (DR) TB, which resulted in global policy changes. This research, conducted by the University of the Witwatersrand and the Clinical HIV Research Unit, formed part of clinical trials involving the Nix-TB and ZeNix studies conducted by the Global TB Alliance. Subsequently, WHO announced key changes to the treatment of DR-TB. Treatment time has been reduced from 18 months to 6 months, and the number of pills reduced from 23 a day to 23 per week, eliminating injections and reducing side effects.

Middle East & Africa Clinical Trials Market Report Highlights

Middle East & Africa Clinical Trials Market Company Profiles

Some of the key players operating in the market QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx Research Private Limited, Caidya, Oracle Corp, Medpace Holdings Inc, and SIRO Clinpharm Pvt Ltd among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Clinical Trials Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Middle East & Africa Clinical Trials Market Country and Regional Insights